InPharm | Rare diseases - pharma's new frontier InPharm In April 2011 Roche and Biogen Idec gained US approval for the use of Rituxan/MabThera (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). |